These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 37480974)

  • 21. Association of Heart Failure With Outcomes Among Patients With Peripheral Artery Disease: Insights From EUCLID.
    Samsky MD; Hellkamp A; Hiatt WR; Fowkes FGR; Baumgartner I; Berger JS; Katona BG; Mahaffey KW; Norgren L; Blomster JI; Rockhold FW; DeVore AD; Patel MR; Jones WS
    J Am Heart Assoc; 2021 Jun; 10(12):e018684. PubMed ID: 34056910
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comprehensive medical management of peripheral arterial disease.
    Gandhi S; Weinberg I; Margey R; Jaff MR
    Prog Cardiovasc Dis; 2011; 54(1):2-13. PubMed ID: 21722781
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Preventive aspects in peripheral artery disease.
    Aggarwal S; Loomba RS; Arora R
    Ther Adv Cardiovasc Dis; 2012 Apr; 6(2):53-70. PubMed ID: 22337767
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Outline of the report on cardiovascular disease in China, 2010.
    Hu SS; Kong LZ; Gao RL; Zhu ML; Wang W; Wang YJ; Wu ZS; Chen WW; Liu MB;
    Biomed Environ Sci; 2012 Jun; 25(3):251-6. PubMed ID: 22840574
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Asymptomatic peripheral arterial disease: is pharmacological prevention of cardiovascular risk cost-effective?
    Sigvant B; Henriksson M; Lundin F; Wahlberg E
    Eur J Cardiovasc Prev Rehabil; 2011 Apr; 18(2):254-61. PubMed ID: 21450673
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Analysis of the control of cardiovascular risk factors in patients with peripheral arterial disease].
    Ferreras Amez JM; Sanjuán Domingo R; Visiedo Sánchez S; Sarrat Torres MA; Vicente Molinero A; Abadía Gallego V; Blasco Valle M
    Semergen; 2013 Mar; 39(2):63-9. PubMed ID: 23452530
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Survival and event-free survival of patients with peripheral arterial disease undergoing prevention of cardiovascular disease.
    Blinc A; Kozak M; Šabovič M; Božič Mijovski M; Stegnar M; Poredoš P; Kravos A; Barbič-Žagar B; Stare J; Pohar Perme M
    Int Angiol; 2017 Jun; 36(3):216-227. PubMed ID: 27332992
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Risk of acute arterial events associated with treatment of inflammatory bowel diseases: nationwide French cohort study.
    Kirchgesner J; Nyboe Andersen N; Carrat F; Jess T; Beaugerie L;
    Gut; 2020 May; 69(5):852-858. PubMed ID: 31446428
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The importance of prevention in high-risk patients: peripheral artery disease, renal failure, and diabetes.
    Crea F
    Eur Heart J; 2024 Apr; 45(15):1287-1290. PubMed ID: 38614813
    [No Abstract]   [Full Text] [Related]  

  • 30. Heart failure is associated with reduced patency after endovascular intervention for symptomatic peripheral arterial disease.
    Meltzer AJ; Shrikhande G; Gallagher KA; Aiello FA; Kahn S; Connolly P; McKinsey JF
    J Vasc Surg; 2012 Feb; 55(2):353-62. PubMed ID: 22051874
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rivaroxaban plus aspirin for the prevention of ischaemic events in patients with cardiovascular disease: a cost-effectiveness study.
    Petersohn S; Pouwels X; Ramaekers B; Ten Cate-Hoek A; Joore M
    Eur J Prev Cardiol; 2020 Sep; 27(13):1354-1365. PubMed ID: 32223323
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Arterial aging impacts on the risk of late-life depressive and cognitive disorders. Is it time for prevention?
    Viscogliosi G; Andreozzi P; Ettorre E; Marigliano V
    Geriatr Gerontol Int; 2014 Jan; 14(1):227-8. PubMed ID: 24405822
    [No Abstract]   [Full Text] [Related]  

  • 33. Polyvascular disease and risk: When two is not better than one.
    Bonaca MP
    Vasc Med; 2018 Dec; 23(6):531-533. PubMed ID: 30232940
    [No Abstract]   [Full Text] [Related]  

  • 34. Antithrombotic therapy in peripheral artery disease--antiplatelet therapy, anticoagulants, both or none.
    Tangelder MJ; van Hattum ES
    Thromb Haemost; 2010 Aug; 104(2):196-9. PubMed ID: 20508897
    [No Abstract]   [Full Text] [Related]  

  • 35. Clinical significance of brachial-ankle pulse-wave velocity in patients with heart failure with preserved left ventricular ejection fraction.
    Tokitsu T; Yamamoto E; Oike F; Hirata Y; Tsujita K; Yamamuro M; Kaikita K; Hokimoto S
    J Hypertens; 2018 Mar; 36(3):560-568. PubMed ID: 29084082
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Resting heart rate: how to use it for cardiovascular prevention?].
    Fassbind M; Yerly P; Nanchen D
    Rev Med Suisse; 2016 Mar; 12(508):454, 456-9. PubMed ID: 27089603
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dual pathway inhibition for atherosclerotic cardiovascular disease: Recent advances.
    Carlin S; de Vries TAC; Budaj A; Eikelboom J
    Kardiol Pol; 2022; 80(12):1200-1210. PubMed ID: 36601884
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prevention of ischemic events in patients with peripheral arterial disease design, baseline characteristics and 2-year results an observational study.
    Blinc A; Kozak M; Sabovic M; Božic M; Stegnar M; Poredoš P; Kravos A; Barbic-Žagar B; Pohar Perme M; Stare J;
    Int Angiol; 2011 Dec; 30(6):555-66. PubMed ID: 22233617
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of risk profiles for cardiovascular events: implications for prevention.
    Kannel WB; Wilson PW
    Adv Intern Med; 1997; 42():39-66. PubMed ID: 9048116
    [No Abstract]   [Full Text] [Related]  

  • 40. Effects of Statin Therapy and Dose on Cardiovascular and Limb Outcomes in Peripheral Arterial Disease: A Systematic Review and Meta-analysis.
    Sofat S; Chen X; Chowdhury MM; Coughlin PA
    Eur J Vasc Endovasc Surg; 2021 Sep; 62(3):450-461. PubMed ID: 34389230
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.